Literature DB >> 19566951

Association study of SHANK3 gene polymorphisms with autism in Chinese Han population.

Jian Qin1, Meixiang Jia, Lifang Wang, Tianlan Lu, Yan Ruan, Jing Liu, Yanqing Guo, Jishui Zhang, Xiaoling Yang, Weihua Yue, Dai Zhang.   

Abstract

BACKGROUND: Autism, a heterogeneous disease, is described as a genetic psychiatry disorder. Recently, abnormalities at the synapse are supposed to be important for the etiology of autism.SHANK3 (SH3 and multiple ankyrin repeat domains protein) gene encodes a master synaptic scaffolding protein at postsynaptic density (PSD) of excitatory synapse. Rare mutations and copy number variation (CNV) evidence suggested SHANK3 as a strong candidate gene for the pathogenesis of autism.
METHODS: We performed an association study between SHANK3 gene polymorphisms and autism in Chinese Han population. We analyzed the association between five single nucleotide polymorphisms (SNPs) of the SHANK3 gene and autism in 305 Chinese Han trios, using the family based association test (FBAT). Linkage disequilibrium (LD) analysis showed the presence of LD between pairwise markers across the locus. We also performed mutation screening for the rare de novo mutations reported previously.
RESULTS: No significant evidence between any SNPs of SHANK3 and autism was observed. We did not detect any mutations described previously in our cohort.
CONCLUSION: We suggest that SHANK3 might not represent a major susceptibility gene for autism in Chinese Han population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19566951      PMCID: PMC2721832          DOI: 10.1186/1471-2350-10-61

Source DB:  PubMed          Journal:  BMC Med Genet        ISSN: 1471-2350            Impact factor:   2.103


Background

Autism is a pervasive developmental disorder mainly characterized by limited or absent verbal communication, lacking of reciprocal social interaction or responsiveness and restricted, stereotypical, and ritualized patterns of interests and behavior. Autism together with childhood disintegrative disorder, pervasive not otherwise specified (PDD-NOS, or atypical autism) and Asperger syndrome share the similar characteristics and are all included as autism spectrum disorder (ASD), also known as pervasive developmental disorder (PDD). Family and twin studies have conclusively described autism as a highly heritable neuropsychiatry disorder with heritability estimates of over 90% and the environmental factors contributing no more than 10% [1-3]. Nevertheless, autism is etiologically heterogeneous. Shank3 (SH3 and multiple ankyrin repeat domains 3; also termed ProSAP2, proline-rich synapse-associated protein 2) is a master synaptic scaffolding protein[4,5]. In rats and human beings, Shank3 is expressed preferentially in cerebral cortex and cerebellum[6,7]. With its multiple protein interaction domains, this molecule directly or indirectly connects with neurotransmitter receptors and cytoskeleton proteins[8,9]. It also participates in the formation, maturation and enlargement of dendritic spines and is essential for the formation of functional synapses[10]. Accumulating discoveries indicate that autism's cause may reside in abnormalities at the synapse[3]. Synapses are the physical sites through which neurons in the brain connect with each other into an integrated circuit. In 2003, the alterations in synaptic function was first proposed to be a possible cause of autism[11]. Neuroligins are a family of postsynaptic cell adhesion molecules and may be involved in the synaptogenesis[12]. Mutations of genes encoding neuroligins (NLGN3, NLGN4X) were supposed to be pathogenic for autism and Asperger syndrome[13]. Neuroligin-deficiency mouse models according to these findings exhibit some deficits that are reminiscent of ASD in human[14,15]. The "neuroligin autim pathway" was postulated[3]. Shank3 acts as a binding partner for neuroligins(NLGNs)[16]. It was reported that rare mutations in SHANK3 may contribute to the pathogenesis of autism. Durand et al. reported two de novo alterations in SHANK3 in subjects with ASD but not in control individuals. One is a G insertion, and the other is a deletion of the terminal 22q13 with the breakpoint in intron8 of SHANK3[17]. Moessner et al. identified de novo variants with an A962G exchange in exon8 leading to a heterozygous Q321R substitution[18]. They also reported a heterozygous deletion encompassing SHANK3 in a female proband but in neither parent nor in two unaffected brothers[18]. Recently Gauthier et al. found a de novo deletion at an intronic splice site in their autistic patients, and this deletion will lead to aberrant splicing of the transcript[19]. SHANK3 could also belong to the "NLGN autism pathway"[1]. All these indicate that SHANK3 might be a strong candidate gene for autism. Resequencing has been applied to identify the rare mutations of this gene, but the linkage and association studies of SHANK3 are still insufficient. In this study, we attempted to investigate the association between the SHANK3 gene polymorphisms and autism in 305 Chinese Han trios on a population-based approach using the family-based association test (FBAT). We also performed mutation screen of this gene in probands with autism in order to detect the rare de novo mutations reported previously.

Methods

Subjects

The sample for this study consisted of 305 Chinese Han family trios (singleton autistic disorder patients and their unaffected biological parents). These families were recruited at the Institute of Mental Health, Peking University, China. Of the 305 autistic child probands, 281 were male and 24 were female. The mean age of the children at the time of testing was 11 years (range 3–25 years). Diagnoses of autism were established by senior psychiatrists. All patients fulfilled the DSM-IV criteria for autistic disorder. The cases were assessed using childhood autism rating scale (CARS)[20] and autism behavior checklist (ABC)[21]. Children with fragile × syndrome, tuberous sclerosis, a previously identified chromosomal abnormality, dysmorphic features, or any other neurological condition suspected to be associated with autism were excluded. All subjects provided written informed consent for participation in this study. The study was approved by the Ethics Committee of the Health Science Center, Peking University.

Genotyping and sequencing

Genomic DNA was extracted from the blood using a Qiagen QIAamp DNA Mini Kit. We selected seven single nucleotide polymorphisms (SNPs) in the SHANK3 gene according to the dbSNP and the international HapMap project , including rs9616915(missense polymorphism), rs2106112(synonymous polymorphism), rs6010065, rs13057681(missense polymorphism), rs2301584(3'UTR), rs41281537 and rs756638. Mutation screen for the rare de novo mutataion reported previously was performed by sequencing exon8 (for A962G[18]), exon21 (for G insertion[17]) and donor splice site G deletion of intron19[19] in all the 305 probands with autism. The SNPs with frequencies of minor allele frequency (MAF) in our sample greater than 5% were used as genetic markers in this study. Three SNPs (rs9616915, rs6010065, rs13057681) were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. Direct DNA sequencing was used for analyzing the other SNPs (rs2106112, rs2301584, rs41281537, rs756638) and detecting the rare de novo mutation reported previously. The information of primers and PCR-RFLP analysis is given in Table 1. The PCR amplification was performed in a 25 μl volume containing GC Buffer (TaKaRa), 200 mM of each dNTPs, 0.3 mM of each primer, 1 U of Taq DNA polymerase, and 40 ng of the genomic DNA. The conditions used for PCR amplification were an initial denaturation phase at 94°C for 5 min, followed by 36 cycles at 94°C for 30 sec, annealing at 60–65°C for 30–60 sec, and extension at 72°C for 30 sec, followed by a final extension phase at 72°C for 7 min. A 15 μL aliquot of the PCR product mixtures was completely digested with 3 units of restriction enzyme overnight. Digestion products were visualized through ethidium bromide staining after electrophoresis in 1%–3% agarose gels. The DNA sequencing was performed after cleaning the PCR product using a BigDye Terminator Cycle Sequencing Ready Reaction Kit with Ampli Taq DNA polymerase (PE Biosystem). The inner primers were used for the cycle-sequencing reaction, and the fragments were separated by electrophoresis on an ABI PRISM 377-96 DNA Sequencer (Applied Biosystem, Foster city, U.S.A).
Table 1

Information of the primers and PCR-RFLP Analysis

SNPPrimer sequence (5'→3')Product (bp)RFLPAllele (bp)
rs9616915Forward: acctgggggcttcacctgactaReverse: cccaacccagcacacagagg207Ava IIT(180/27)C(121/59/27)
rs13057681Forward: ccgcaagagccccctggtgaReverse: caggaggcgctcgtcgatggag328Sty IG(198/130)C(328)
rs6010065Forward: ccttacctgggtgggcattReverse: acggggagggctcttgtg423Hinf IG(166/257)C(423)
rs2106112Forward: ctgagccactcggaggttgctReverse: gtccgaccttcaccacgttcac340
rs2301584, rs41281537, rs756638Forward: cgccaacagtccaggtcacReverse: cagaaggcatgggctgagtt489
G insertion in exon21Forward: cgggaggagcggaagtcacReverse: ggaccccgttggcaaactct409
A962G in exon8Forward: cgcacgccatgtgtgcattcctReverse: tctcggggttggggggtcagac473
splice doner site of intron19Forward: gcctggggtggggtctgagReverse: ttggagcctgggctgtgtg754

PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; SNP, single nucleotide polymorphism.

Information of the primers and PCR-RFLP Analysis PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; SNP, single nucleotide polymorphism.

Statistical analyses

Deviation from the Hardy-Weinberg equilibrium (HWE) for genotype frequency distributions was analyzed using the Chi-square goodness-of-fit test. To perform single- and multi-locus tests of association, we used the FBAT program (v. 1.5.1)[22]. The FBAT program uses a generalized score statistic to perform a variety of transmission disequilibrium tests, including haplotype analysis. Moreover, the FBAT program provides pairwise linkage disequilibrium (LD) analysis to detect an inter-marker relationship, using D' values. SNP pairs were considered to be in strong LD if D' > 0.70. The global haplotype tests of association were performed under "multiallelic" mode in haplotype FBAT. Meanwhile, the individual haplotype tests were conducted under "biallelic" mode in haplotype FBAT. Family-based association tests were performed under an additive model in the present study. The significance level for all statistical tests was two-tailed P < 0.05.

Results

Seven SNPs in SHANK3 gene were genotyped in 305 Chinese Han autism trios. SNPs rs2106112 and rs13057681 were not polymorphic in our samples. They were not used as genetic markers for the association analyses. The other five SNPs (rs9616915, rs6010065, rs2301584, rs41281537, rs756638) were polymorphic with MAF > 5% and were then used as genetic markers for the association study. None of the genotype distributions of these five SNPs in parents or patients deviated from Hardy-Weinberg equilibrium (data not shown). Allele frequencies and the results of FBAT for single SNP analyses are shown in Table 2. None of the five SNPs was significant evidence (P < 0.05) for preferential transmission of an allele by FBAT in all samples. To further analyze the pattern of linkage disequilibrium (LD) in our sample, we computed pairwise LD for all possible combination of the five SNPs using D' values (Table 3). Four SNPs (rs6010065, rs2301584, rs41281537, rs756638) were found to be in strong LD with each other (D' > 0.7) except for rs9616915 (Table 3). To determine whether any specific haplotype would confer a higher risk for autism, we tested all specific and globe haplotype composed of these SNPs. Two haplotypes displayed weak association with autism. These are C-G-G-A (rs6010065- rs2301584- rs41281537- rs756638, P = 0.040) and G-A (rs41281537- rs756638, P = 0.047), respectively (Table 3). After 1,000 permutation tests the haplotype C-G-G-A was still associated with autism (P = 0.041), but no significance remained in the haplotype G-A (P = 0.050). No statistically significant association (P < 0.05) was observed for any other haplotypes in any set of families in HBAT analyses (data not shown). Moreover, the entire global test for haplotype transmission revealed a negative result (data not shown). To detect the de novo mutations reported before, we sequenced the exon8 (for A962G)[18], part of exon21 (for G insertion)[17], the donor splice site of intron19[19] of SHANK3 in 305 probands. However, we didn't find any genetic variants or the mutations reported previously.
Table 2

Results of FBAT for the five SNPs

MakersAlleleAfreqFamiliesSE (S)Var (S)ZP-values
rs9616915T0.91187128.000123.50024.7500.9050.365
C0.0898746.00050.50024.750-0.9050.365
rs6010065G0.500235242.000236.50079.2500.6180.536
C0.500235228.000233.50079.250-0.6180.536
rs2301584G0.811159218.000217.00046.0000.1470.882
A0.189159100.000101.00046.000-0.1470.882
rs41281537G0.858133188.000189.50037.750-0.2440.807
A0.14213378.00076.50037.7500.2440.807
rs756638G0.812155218.000213.00045.5000.7410.458
A0.18815592.00097.00045.500-0.7410.458

FBAT, family-based association test; Afreq, allelic frequency. Families, number of informative families; S, test statistics for the observed number of transmitted alleles; E(S), expected value of S under the null hypothesis (i.e., no linkage or association). Significant P values (< 0.05) are in boldface.

Table 3

Measure of Pairwise Linkage Disequilibrium D (D') Between Five SNPs in SHANK3 gene

rs9616915rs6010065rs2301584rs41281537
rs6010065-0.024(0.58)
rs2301584-0.003(0.21)0.082(0.87)
rs41281537-0.010(0.82)0.068(0.95)-0.023(0.86)
rs756638-0.007(0.44)0.081(0.86)-0.027(0.77)0.115(1.00)
Results of FBAT for the five SNPs FBAT, family-based association test; Afreq, allelic frequency. Families, number of informative families; S, test statistics for the observed number of transmitted alleles; E(S), expected value of S under the null hypothesis (i.e., no linkage or association). Significant P values (< 0.05) are in boldface. Measure of Pairwise Linkage Disequilibrium D (D') Between Five SNPs in SHANK3 gene The SHANK3 gene spans about 60 kb. In Affimatrix SNP 5.0 chip of 240 trios from this sample, it included 16 CNV probes covering SHANK3 gene and its flanking region. The smallest distance between two probes was less than 500 bp. In these probes, one CNV probe was located at intron8 which was reported as a breakpoint of a de novo deletion[17], and a few CNV probes were quite close to exon21 which was reported as a breakpoint of a de novo translocation in 22q13 deletion syndrome[7]. However, we didn't find any genomic imbalance in all these 240 trios or control (unpublished data).

Discussion

Shank3 is a master synaptic scaffolding protein, acting as the bridge of some neurotransmitter receptors and the downstream signal transduction. It has been postulated to perform important roles in excitatory synapse assembly [23-26], dendritic formation and maturation[10,27,28]. The de novo alterations of this gene and their roles in the pathogenesis of autism have been reported by some studies [17-19]. Based on this evidence, we hypothesized that the SHANK3 might be a strong candidate gene for autism. However, there was few evidence of association between SHANK3 polymorphisms and autism. In the present study, we investigated the association of SHANK3 polymorphisms and autism in 305 Chinese Han trios. We detected seven dbSNPs of SHANK3, including two nonpolymorphic SNPs rs2106112 (synonymous mutation) and rs13057681 (H1033D) in our samples. In a family-based association study for all the other five SNPs we found no evidence for transmission disequilibrium for any single marker (P > 0.05), even for the missense SNP rs9616915C>T which was reported as a non-synonymous variant identified in ASD[19]. In attempt to identify de novo genetic variants in SHANK3 that had been reported previously, we performed mutation screen of exon8, part of exon21, the donor slpice site of intron19 of SHANK3 in 305 probands with autism, and only identified one novel synonymous variant (T1231). In addition, the specific and global-haplotype FBAT tests of association were performed. Four SNPs were located in a block with high LD including rs6010065, rs2301584, rs41281537, rs756638. However, only C-G-G-A (rs6010065- rs2301584- rs41281537- rs756638, P = 0.040) exhibited a weak association with autism in our sample. We didn't detect any genomic imbalance of SHANK3 and its flanking region in our sample using Affimetrix 5.0 chip either. Our finding suggested that SHANK3 doesn't represent a major susceptibility gene for autism in the autism families ascertained from Chinese Han population. Several potential reasons might explain the difference among various reports about SHANK3 gene and autism. One might be the racial and ethnic differences in genotype distribution and association with autism risk. For example, the allele frequency of the SHANK3 non-synonymous SNP rs9616915 was obviously different between Chinese and the other populations in the National Center for Biotechnology Information (NCBI) gene database. For European (CEU), and Nigeria population, the frequencies of allele C are 0.533 and 0.383 respectively, but for Chinese Han population (CHB) it is 0.044. Further, the variety of the investigated samples should be noticed. The previous evidence about SHANK3 was always from subjects with ASD, including autism, Asperger syndrome and PDD-NOS. Our autism cases only include patients with infantile autism, and not other cases of the etiologically more heterogeneous ASD. The heterogeneity of the investigated samples combined with the heterogeneity of neurodevelopmental disorders might hamper the understanding of genetic factors associated with autism. In order to enhance the possibility of finding relevant genetic cause, the phenotype variability in sample should be reduced[29]. In the present study we examined a relatively homogenous sample of autism to reduce the heterogeneity. The location of SHANK3 is at 22q13.3, which is a critical region for 22q13 deletion syndrome that also has autistic behavior. There are strong evidence that haploinsufficiency of SHANK3 plays a major role in 22q13 deletion syndrome[30]. SHANK3 is very likely to be involved in the pathogenesis of some mutual phenotypes of ASD and 22q13 deletion syndrome, such as delay of expressive speech. Furthermore, 22q13 deletion syndrome has a clinical phenotype overlapping in part the ASD phenotype. So subjects with 22q13 deletion may be included in ASD samples. It is really critical for the researches on autism to exclude the 22q13 deletion syndrome. We didn't detect any genomic imbalance of 22q13 in our samples using Affimetrix SNP 5.0 chip. Moreover, although the disruption of SHANK3 seems to be associated with 22q13 deletion syndrome, there is also contrary evidence that the haploinsufficiency for 22q13 genes other than SHANK3 have major effects[31]. The present study indicates that SHANK3 may not be a critical gene for the etiology of infantile autism in Chinese Han population. As autism is a heterogeneous disease, the rare mutations of SHANK3 gene seem to explain the etiology of only a small proportion of cases with autism. Sykes et al. reported recently that they didn't find any CNV or SNP association of SHANK3 within their ASD sample, although they didn't sequence the gene[32]. Their suggestion that SHANK3 deletions may be limited to a portion of autism was coincident with ours. There was few association or linkage study for SHANK3 and autism. Our family-based association study provided an indication that SHANK3 was not critical for the pathogenesis of autism in Chinese Han population or only account for a small proportion of autism individuals. In addition, our results also reinforce the need for the detailed LD mapping, mutation screening and CNV analysis of SHANK3 in different population or other neurodevelopmental disorders.

Conclusion

The present study did not find strong evidence of SHANK3 polymorphisms and autism or identify any described non-synonymous mutations in our cohort. These might indicate that SHANK3 doesn't represent a major susceptibility gene for autism in the autism families ascertained from Chinese Han population.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

JQ carried out sequencing and PCR-RFLP analysis, and contributed to manuscript writing. MJ performed the statistical analysis and most of the sample collection. LW aided in statistical analysis. TL and YR aided in sample storage and preparations. JL, YG, JZ and XY contributed to the sample collection. WY and DZ participated in the design of the study and manuscript writing.

Pre-publication history

The pre-publication history for this paper can be accessed here:
  32 in total

Review 1.  Synapse structure: glutamate receptors connected by the shanks.

Authors:  M D Ehlers
Journal:  Curr Biol       Date:  1999-11-18       Impact factor: 10.834

Review 2.  Molecular morphogens for dendritic spines.

Authors:  Michael D Ehlers
Journal:  Trends Neurosci       Date:  2002-02       Impact factor: 13.837

3.  Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism.

Authors:  Stéphane Jamain; Hélène Quach; Catalina Betancur; Maria Råstam; Catherine Colineaux; I Carina Gillberg; Henrik Soderstrom; Bruno Giros; Marion Leboyer; Christopher Gillberg; Thomas Bourgeron
Journal:  Nat Genet       Date:  2003-05       Impact factor: 38.330

4.  Disruption of the ProSAP2 gene in a t(12;22)(q24.1;q13.3) is associated with the 22q13.3 deletion syndrome.

Authors:  M C Bonaglia; R Giorda; R Borgatti; G Felisari; C Gagliardi; A Selicorni; O Zuffardi
Journal:  Am J Hum Genet       Date:  2001-06-18       Impact factor: 11.025

5.  Postnatal neurodevelopmental disorders: meeting at the synapse?

Authors:  Huda Y Zoghbi
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

6.  Linkage of the actin cytoskeleton to the postsynaptic density via direct interactions of Abp1 with the ProSAP/Shank family.

Authors:  Britta Qualmann; Tobias M Boeckers; Monika Jeromin; Eckart D Gundelfinger; Michael M Kessels
Journal:  J Neurosci       Date:  2004-03-10       Impact factor: 6.167

7.  Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms.

Authors:  H L Wilson; A C C Wong; S R Shaw; W-Y Tse; G A Stapleton; M C Phelan; S Hu; J Marshall; H E McDermid
Journal:  J Med Genet       Date:  2003-08       Impact factor: 6.318

Review 8.  ProSAP/Shank proteins - a family of higher order organizing molecules of the postsynaptic density with an emerging role in human neurological disease.

Authors:  Tobias M Boeckers; Jürgen Bockmann; Michael R Kreutz; Eckart D Gundelfinger
Journal:  J Neurochem       Date:  2002-06       Impact factor: 5.372

Review 9.  The Shank family of scaffold proteins.

Authors:  M Sheng; E Kim
Journal:  J Cell Sci       Date:  2000-06       Impact factor: 5.285

10.  Copy number variation and association analysis of SHANK3 as a candidate gene for autism in the IMGSAC collection.

Authors:  Nuala H Sykes; Claudio Toma; Natalie Wilson; Emanuela V Volpi; Inês Sousa; Alistair T Pagnamenta; Raffaella Tancredi; Agatino Battaglia; Elena Maestrini; Anthony J Bailey; Anthony P Monaco
Journal:  Eur J Hum Genet       Date:  2009-04-22       Impact factor: 4.246

View more
  15 in total

1.  Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: a systematic review.

Authors:  Jordi Soler; Lourdes Fañanás; Mara Parellada; Marie-Odile Krebs; Guy A Rouleau; Mar Fatjó-Vilas
Journal:  J Psychiatry Neurosci       Date:  2018-05-28       Impact factor: 6.186

2.  Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: a systematic review.

Authors:  Jordi Soler; Lourdes Fañanás; Mara Parellada; Marie-Odile Krebs; Guy A Rouleau; Mar Fatjó-Vilas
Journal:  J Psychiatry Neurosci       Date:  2018-07       Impact factor: 6.186

Review 3.  Modeling of Autism Using Organoid Technology.

Authors:  Hwan Choi; Juhyun Song; Guiyeon Park; Jongpil Kim
Journal:  Mol Neurobiol       Date:  2016-11-14       Impact factor: 5.590

4.  Sociability and motor functions in Shank1 mutant mice.

Authors:  Jill L Silverman; Sarah M Turner; Charlotte L Barkan; Seda S Tolu; Roheeni Saxena; Albert Y Hung; Morgan Sheng; Jacqueline N Crawley
Journal:  Brain Res       Date:  2010-09-21       Impact factor: 3.252

5.  A commonly carried genetic variant, rs9616915, in SHANK3 gene is associated with a reduced risk of autism spectrum disorder: replication in a Chinese population.

Authors:  Shanshan Shao; Sanqing Xu; Jun Yang; Ti Zhang; Zhen He; Zhao Sun; Ranran Song
Journal:  Mol Biol Rep       Date:  2014-01-08       Impact factor: 2.316

6.  Prevalence of SHANK3 variants in patients with different subtypes of autism spectrum disorders.

Authors:  Luigi Boccuto; Maria Lauri; Sara M Sarasua; Cindy D Skinner; Daniela Buccella; Alka Dwivedi; Daniela Orteschi; Julianne S Collins; Marcella Zollino; Paola Visconti; Barb Dupont; Danilo Tiziano; Richard J Schroer; Giovanni Neri; Roger E Stevenson; Fiorella Gurrieri; Charles E Schwartz
Journal:  Eur J Hum Genet       Date:  2012-08-15       Impact factor: 4.246

Review 7.  [Genetic and brain structure anomalies in autism spectrum disorders. Towards an understanding of the aetiopathogenesis?].

Authors:  T Nickl-Jockschat; T M Michel
Journal:  Nervenarzt       Date:  2011-05       Impact factor: 1.214

8.  A double hit implicates DIAPH3 as an autism risk gene.

Authors:  J A S Vorstman; E van Daalen; G R Jalali; E R E Schmidt; R J Pasterkamp; M de Jonge; E A M Hennekam; E Janson; W G Staal; B van der Zwaag; J P H Burbach; R S Kahn; B S Emanuel; H van Engeland; R A Ophoff
Journal:  Mol Psychiatry       Date:  2010-03-23       Impact factor: 15.992

9.  The 22q13.3 Deletion Syndrome (Phelan-McDermid Syndrome).

Authors:  K Phelan; H E McDermid
Journal:  Mol Syndromol       Date:  2011-11-22

10.  Reduced excitatory neurotransmission and mild autism-relevant phenotypes in adolescent Shank3 null mutant mice.

Authors:  Mu Yang; Ozlem Bozdagi; Maria Luisa Scattoni; Markus Wöhr; Florence I Roullet; Adam M Katz; Danielle N Abrams; David Kalikhman; Harrison Simon; Leuk Woldeyohannes; James Y Zhang; Mark J Harris; Roheeni Saxena; Jill L Silverman; Joseph D Buxbaum; Jacqueline N Crawley
Journal:  J Neurosci       Date:  2012-05-09       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.